Molecular Partner…
CHCHFMolecular Partners AG (US:MLLCF) — Biotechnology: Biological Products (No Diagnostic Substances). Broj burzi na kojima se trguje dionicama tvrtke: 3. Na ovoj stranici — cijena i grafikon, dividende, najveći dioničari i povijest broja dionica.
O Tvrtki
- Web-Stranica
- molecularpartners.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sjedište
- Schlieren-Zurich, Switzerland
- Glavni Direktor
- Patrick Amstutz
- Zaposlenici
- 134
- Dionice u Optjecaju
- 38.31 mil.
- Slobodno Prenosive Dionice
- 20.71 mil.
- Tržišna Kapitalizacija
- 127.56 mil. CHF
- Insajderi
- 8.47%
- Institucionalni Ulagači
- 43.8%
- Djelatnost (SIC)
- Biological Products, (No Diagnostic Substances)
- Pravni Oblik
- MVII
- ISIN
- US60853G1067
- LEI
- 875500AXMLDAZ4D21744
- FCF
- −52.0 mil. CHF
- Dug
- ?
- Zarada i FCF — za 12 mjeseci do 31.12.2025 (najnovije izvješće tvrtke).
Opis
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Najveći Imatelji
| Imatelj | Udio | Dionice | Datum Izvješća |
|---|---|---|---|
| Old Mission Capital, LLC | 0.03% | 11 347 | 2025-06-30 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 923 | 2026-07-31 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 503 | 2026-07-31 |
| American Century ETF Tru… | 0% | 12 | 2026-08-31 |
Prijavite se s Google